Last quarter (Q4 2023), HLS Therapeutics Inc's total revenue was $15.86M, an increase of 1.20% from the same quarter last year. In Q4, HLS Therapeutics Inc's net income was $-5.40M. See HLS Therapeutics Inc’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	$ 63.07M	$ 63.07M	$ 61.47M	$ 60.01M	$ 56.11M	$ 54.16M
Cost of Revenue	$ 7.62M	$ 7.62M	$ 4.98M	$ 3.97M	$ 3.63M	$ 1.93M
Gross Profit	$ 55.45M	$ 55.45M	$ 56.49M	$ 56.04M	$ 52.48M	$ 52.23M
Operating Expense	$ 69.58M	$ 69.58M	$ 70.78M	$ 62.32M	$ 64.57M	$ 56.86M
Operating Income	$ -14.13M	$ -14.13M	$ -14.29M	$ -6.28M	$ -12.09M	$ -4.63M
Net Non Operating Interest Income Expense	$ -8.40M	$ -8.40M	$ -7.26M	$ 6.91M	$ -5.99M	$ -7.11M
Other Income Expense	$ 5.32M	$ 5.32M	$ -2.33M	$ 1.39M	$ 1.77M	$ -8.72M
Pretax Income	$ -27.80M	$ -27.80M	$ -23.72M	$ -11.81M	$ -16.30M	$ -20.46M
Tax Provision	$ -272.00K	$ -272.00K	$ -124.00K	$ 1.31M	$ -968.00K	$ -911.00K
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -27.53M	$ -27.53M	$ -23.60M	$ -13.12M	$ -15.33M	$ -19.55M
Basic EPS	-	-	-	-	$ -0.48	$ -0.67
Diluted EPS	-	-	-	-	$ -0.48	$ -0.67
Basic Average Shares	-	-	-	-	$ 31.71M	$ 29.36M
Diluted Average Shares	-	-	-	-	$ 31.71M	$ 29.36M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 77.21M	$ 77.21M	$ 75.76M	$ -66.29M	$ 68.20M	$ 58.79M
Net Income From Continuing And Discontinued Operation	$ -27.53M	$ -27.53M	$ -23.60M	$ -13.12M	$ -15.33M	$ -19.55M
Normalized Income	$ -20.49M	$ -24.18M	$ -19.45M	$ -8.51M	$ -16.52M	$ -11.22M
Interest Expense	-	-	-	-	$ 6.31M	$ 7.70M
EBIT	$ -19.05M	$ -19.05M	$ -16.41M	$ -4.85M	$ -9.99M	$ -12.76M
EBITDA	$ 12.88M	$ 12.88M	$ 18.00M	$ 25.41M	$ 23.19M	$ 19.75M

Currency in USD

HLS Therapeutics Inc Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing